STOCK TITAN

Wave Life Scienc Stock Price, News & Analysis

WVE Nasdaq

Welcome to our dedicated page for Wave Life Scienc news (Ticker: WVE), a resource for investors and traders seeking the latest updates and insights on Wave Life Scienc stock.

Wave Life Sciences Ltd. (NASDAQ: WVE) is a clinical-stage biotechnology leader advancing RNA medicines through its proprietary PRISM platform. This page provides investors and researchers with timely updates on the company's stereopure oligonucleotide therapies targeting genetic disorders.

Access the latest press releases covering clinical trial progress, regulatory milestones, and scientific advancements. Our curated collection includes updates across WVE's pipeline, including programs for Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency, and neurological conditions.

Key news categories include:
• Clinical development updates
• Strategic research collaborations
• Regulatory pathway announcements
• Scientific publication highlights

Bookmark this page for direct access to primary source materials about WVE's innovative approach to RNA editing and antisense technologies. Monitor critical developments in precision genetic medicine through verified company communications.

Rhea-AI Summary

Wave Life Sciences (Nasdaq: WVE) announced that CEO Paul Bolno will present at the RBC Capital Markets Global Healthcare Virtual Conference on May 19, 2021, at 4:15 p.m. ET. This presentation will be streamed live and can be accessed via the company's investor relations page. Following the event, a replay will be available for 90 days. Wave Life Sciences is dedicated to developing innovative genetic medicines to treat severe diseases, utilizing its proprietary discovery platform, PRISM.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.49%
Tags
conferences
-
Rhea-AI Summary

Wave Life Sciences Ltd. (Nasdaq: WVE) will host a live webcast and conference call on May 13, 2021, at 8:30 a.m. ET to discuss its Q1 2021 financial results and provide a business update. This event will be accessible via their Investor Relations page. As a clinical-stage genetic medicines company, Wave focuses on innovative treatments for serious diseases through its proprietary PRISM platform that enhances the design and production of stereopure oligonucleotides.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.68%
Tags
conferences earnings
-
Rhea-AI Summary

Wave Life Sciences Ltd. (Nasdaq: WVE) has announced results from its PRECISION-HD trials, revealing no significant efficacy for investigational treatments WVE-120102 and WVE-120101 in reducing mutant huntingtin protein (mHTT) in Huntington's disease patients. Consequently, clinical development for both candidates will be halted. However, the company is advancing its novel WVE-003 program with improvements in pharmacology and allele-selectivity targeted at SNP3. Wave plans to initiate dosing for WVE-003 in 2021, showcasing commitment to developing therapies that spare healthy wild-type huntingtin protein.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.94%
Tags
Rhea-AI Summary

Wave Life Sciences Ltd. (Nasdaq: WVE) announced that CEO Paul Bolno and CMO Michael Panzara will participate in a virtual fireside chat at the Third Annual Stifel CNS Day on April 1, 2021, at 11:30 a.m. ET. Investors can access the presentation live via the company's investor relations page, with a replay available for 90 days afterward. Wave Life Sciences focuses on developing genetic medicines through its proprietary PRISM platform, targeting a range of genetically defined diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.65%
Tags
conferences
-
Rhea-AI Summary

Wave Life Sciences (WVE) reported a $28.8 million net loss for Q4 2020, down from $56.8 million in Q4 2019. For the full year, net loss was $149.9 million, improved from $193.6 million. R&D expenses decreased to $30 million in Q4 2020 from $49.1 million in Q4 2019, driven by cost reductions. Wave plans to advance five clinical programs in 2021, including novel therapies for Huntington’s disease and ALS. The company ended 2020 with $184.5 million in cash, projected to last into Q2 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.79%
Tags
-
Rhea-AI Summary

Wave Life Sciences (Nasdaq: WVE) announced a live webcast and conference call scheduled for March 4, 2021, at 8:00 a.m. ET to discuss its fourth quarter and full year 2020 financial results. The company focuses on developing innovative genetic medicines using proprietary technology aimed at treating genetically defined diseases. Investors can access the call via the company's Investor Relations page or by phone. An archived version will be available post-call.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.8%
Tags
conferences earnings
Rhea-AI Summary

Wave Life Sciences (Nasdaq: WVE) announced that CEO Paul Bolno will participate in an analyst-led fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference on February 25, 2021, at 5:00 p.m. ET. The event will be accessible via a live webcast on the company's investor relations page, with a replay available for 90 days post-event. Wave Life Sciences focuses on developing innovative therapies for genetically defined diseases through its proprietary PRISM platform, aiming to create effective treatments and improve patient outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.85%
Tags
conferences
-
Rhea-AI Summary

Wave Life Sciences (Nasdaq: WVE) announced key milestones for 2021, including the initiation of three clinical trials utilizing novel PN backbone chemistry. These studies will target Huntington’s disease, amyotrophic lateral sclerosis, frontotemporal dementia, and Duchenne muscular dystrophy. Data from ongoing PRECISION-HD trials for Huntington’s disease is expected by the end of Q1 2021, aiding potential Phase 3 decision-making. Wave's proprietary PRISM platform continues to advance, with in vivo data for alpha-1 antitrypsin deficiency anticipated in the first half of 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.96%
Tags
none
-
Rhea-AI Summary

Wave Life Sciences Ltd. (Nasdaq: WVE) has appointed Jonathan Rosin as the new Chief Human Resources Officer (CHRO). With over 25 years of HR experience, Rosin aims to enhance Wave's clinical trial support and organizational development. His prior role as CHRO at Ironwood Pharmaceuticals involved significant cultural and capability advancements. Rosin received stock options for 53,000 shares and 27,000 restricted shares as part of his compensation. This strategic leadership change intends to foster growth and maintain Wave's unique culture while advancing their drug development efforts.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.68%
Tags
management
Rhea-AI Summary

Wave Life Sciences Ltd. (Nasdaq: WVE) is set to present at the 29th Annual Credit Suisse Healthcare Conference on November 11, 2020, at 5:00 p.m. ET. Dr. Paul Bolno, President and CEO, will deliver the presentation. A live webcast can be accessed through the company's Investor Relations page, with a recording available for 60 days post-event. Wave Life Sciences focuses on developing innovative genetic treatments using its proprietary PRISM platform to design and optimize stereopure oligonucleotides, addressing various genetically defined diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.8%
Tags
conferences

FAQ

What is the current stock price of Wave Life Scienc (WVE)?

The current stock price of Wave Life Scienc (WVE) is $6.515 as of July 1, 2025.

What is the market cap of Wave Life Scienc (WVE)?

The market cap of Wave Life Scienc (WVE) is approximately 1.1B.
Wave Life Scienc

Nasdaq:WVE

WVE Rankings

WVE Stock Data

1.06B
130.28M
16.53%
83.51%
5.97%
Biotechnology
Pharmaceutical Preparations
Link
Singapore
SINGAPORE